Triptolide Inhibits MCF-7 and HepG2 Cells Invasion and Migration by Inhibiting the Synthesis of Polylactosamine Chains
Keywords:Triptolide, polylactosamine, 3-N-acetylglucosamine transferase, tumor, invasion, migration.
Triptolide is a bioactive natural products isolated from Tripterygium wilfordii, a traditional Chinese herbal medicine. Clinical studies reveal that triptolide can be used in autoimmune disorders, such as rheumatoid arthritis, kidney disease and systemic lupus erythematosus. Recently, some studies revealed that triptolide has anti-tumor effects, which attracts more and more attention. This experiment aimed to explore the relationship between anti-tumor effects of triptolide and N-type polylactosamine. With increasing the concentration of triptolide, the viability of MCF-7 and HepG2 cells was reduced significantly and the polylactosamine expression on these cells declined as well. In addition, the expression of β1, 3-N-acetylglucosamine transferase (β3GnT8) participated in catalyzing the synthesis of N-type polylactosamine was also decreased and the expression of genes and proteins of downstream signaling was altered consequently. Finally, triptolide weakened the cancer cells invasion and migration. All of these indicate that triptolide can impair MCF-7 and HepG2 cells invasion and migration through downregulating the expression of polylactosamine chains. These studies establish that triptolide is a potential novel therapy in breast cancer and hepatic carcinoma
Zheng Y, Zhang WJ and Wang XM. Triptolide with potential medicinal value for diseases of the central nervous system. CNS Neurosci Ther 2013; 19: 76-82. http://dx.doi.org/10.1111/cns.12039
Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 2011; 11: 377-383. http://dx.doi.org/10.1016/j.intimp.2011.01.012
Li Y and Hu S. Triptolide sensitizes liver cancer cell lines to chemotherapy in vitro and in vivo. Panminerva Med 2014; 56: 211-20.
Yang S, Chen J, Guo Z, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003; 2: 65-72.
Reno TA, Kim JY and Raz DJ. Triptolide Inhibits Lung Cancer Cell Migration, Invasion and Metastasis. The Annals of Thoracic Surgery 2015; 100: 1817-24. http://dx.doi.org/10.1016/j.athoracsur.2015.05.074
Johnson SM, Wang X and Evers BM. Triptolide inhibits proliferation and migration of colon cancer cells by inhibition of cell cycle regulators and cytokine receptors. J Surg Res 2011; 168: 197-205. http://dx.doi.org/10.1016/j.jss.2009.07.002
Carter BZ, Mak DH, Schober WD, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006; 108: 630-637. http://dx.doi.org/10.1182/blood-2005-09-3898
Tong X, Zheng S, Iin J, et al. Triptolide inhibits cyclooxygeriase-2 and inducible nitric oxide synthase expression in human colon cancer and leukemia cells. Aeta Bioch Biophy Sini 2007; 39: 89-95. http://dx.doi.org/10.1111/j.1745-7270.2007.00254.x
Wang X, Matta R, Shen G, et al. Mechanism of triptolide-induced apoptosis: Effect on caspase activation and Bid cleavage and essentiality of the hydroxyl group of triptolide. J Molecu Med 2006; 84: 405-415. http://dx.doi.org/10.1007/s00109-005-0022-4
Manzo S, Zhou ZL, Wang YQ, Marinello J, He JX, Li YC, et al. Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II. Cancer Res 2012; 72: 5363-73. http://dx.doi.org/10.1158/0008-5472.CAN-12-1006
Wang Y, Lu JJ, He L and Yu Q. Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). PLoS One 2011; 6: e23993. http://dx.doi.org/10.1371/journal.pone.0023993
Drake PM, Cho W, Li B, Prakobphol A, Johansen E, Anderson NL, Regnier FE, Gibson BW and Fisher SJ. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin. Chem 2010; 56: 223-236. http://dx.doi.org/10.1373/clinchem.2009.136333
Fuster MM and Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005; 5: 526-542. http://dx.doi.org/10.1038/nrc1649
Stanley P. Biological consequences of overexpressing or eliminating N-acetylglucosaminyl transferase-TIII in the mouse. Biochim Biophys Acta 2002; 1573: 363-8. http://dx.doi.org/10.1016/S0304-4165(02)00404-X
Guo JM, Chen HL, Wang GM, et al. Expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-12 in gastric and colonic cancer cell lines and in human colorectal cancer. Oncology 2004; 67: 271-6. http://dx.doi.org/10.1159/000081328
Li Shen, Zhenhua Liu, Youbin Tu, et al. Regulation of MMP-2 expression and activity by β1, 3-N-acetylglucosaminyl-transferase-8 in AGS gastric cancer cells. Mol Biol Rep 2011; 38: 1541-50. http://dx.doi.org/10.1007/s11033-010-0262-4
Akira Seko and Katsuko Yamashita. Characterization of a novel galactose β1, 3-N-acetylglucosaminyltransferase (β3GnT8): the complex formation of β3GnT2 and β3GnT8 enhances enzymatic activity. Glycobiology 2005; 15: 943-51. http://dx.doi.org/10.1093/glycob/cwi082
Sun J and Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metallopro-teinase inducer interactions. Cancer Res 2001; 61: 2276-81.
Gabison EE, Hoang-Xuan T, Mauviel A, et al. EMMPRIN/ CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 2005; 87: 361-8. http://dx.doi.org/10.1016/j.biochi.2004.09.023
Lu H, Hu L, Yu L, et al. KLF8 and FAK cooperatively enrich the active MMP14 on the cell surface required for the metastatic progression of breast cancer. Oncogene 2014; 33: 2909-17. http://dx.doi.org/10.1038/onc.2013.247
Tang W, Chang SB and Hemler ME. Links between CD147 function, glycosylation, and caveolin-1. Mol Bid Cell 2004; 15: 4043-50. http://dx.doi.org/10.1091/mbc.E04-05-0402
Yosuke Mitsuia, Keita Yamada, Sayaka Hara, et al. Comparative studies on glycoproteins expressing polylactosamine-type N-glycans in cancer cells. Journal of Pharmaceutical and Biomedical Analysis 2012; 70: 718-26. http://dx.doi.org/10.1016/j.jpba.2012.06.035
Fan J, Wang S, Yu S, et al. N-acetylglucosaminyltransferase IVa regulates metastatic potential of mouse hepatocarcinoma cells through glycosylation of CD147. Glycoconj J. 2012; 29: 323-34. http://dx.doi.org/10.1007/s10719-012-9414-1
Huang W, Luo WJ, Zhu P, et al. Modulation of CD147-induced matrix metalloproteinase activity: role of CD147 N-glycosylation. Biochem J 2013; 449: 437-48. http://dx.doi.org/10.1042/BJ20120343
Shen L, Yu M, Xu X, et al. Knockdown of β3GnT8 reverses 5‑fluorouracil resistance in human colorectal cancer cells via inhibition the biosynthesis of polylactosamine‑type N‑glycans. Int J Oncol 2014; 45: 2560-8. http://dx.doi.org/10.3892/ijo.2014.2672
Gao L, Shen L, Yu M, et al. Colon cancer cells treated with 5‑fluorouracil exhibit changes in polylactosamine‑type N‑glycans. Mol Med Rep 2014; 9: 1697-702. http://dx.doi.org/10.3892/mmr.2014.2008
Ni J, Jiang Z, Shen L, et al. β3GnT8 regulates the metastatic potential of colorectal carcinoma cells by altering the glycosylation of CD147. Oncol Rep 2014; 31: 1795-801. http://dx.doi.org/10.3892/or.2014.3042